Mission Statement, Vision, & Core Values of Passage Bio, Inc. (PASG)

Ever wondered what drives a company focused on developing genetic medicines for neurodegenerative diseases? What are the guiding principles behind their quest to redefine the course of these conditions? Let's delve into the mission, vision, and core values that steer Passage Bio, Inc. (PASG), a clinical-stage genetic medicines company, particularly in light of their recent financial performance, with a $76.8 million cash position as of December 31, 2024, and R&D expenses of $40.2 million for the year.

How do these elements align with their strategic advancements, such as the upliFT-D trial and expansion into FTD-C9orf72 patients, and what impact do they have on the company's operations and future direction, especially with their cash runway extended into Q1 2027? Understanding these foundational aspects can provide valuable insight into their goals and how they aim to achieve them.

What role do these values play in their commitment to patients and communities, and how do they influence the company's approach to innovation and collaboration? Read on to explore the core of what makes this company tick.

Passage Bio, Inc. (PASG) An Overview of

Founded with a focus on developing transformative genetic medicines for central nervous system (CNS) disorders, Passage Bio has been dedicated to addressing the unmet needs of patients with rare monogenic diseases. Although Passage Bio faced challenges and ultimately ceased operations, its initial mission was centered on leveraging adeno-associated virus (AAV) vectors to deliver gene therapies that could potentially alter the course of these debilitating conditions. The company's efforts primarily targeted disorders with limited or no effective treatment options, reflecting a commitment to innovation in the field of genetic medicine.

While Passage Bio no longer offers active products or services due to the cessation of its operations, its historical focus was on the development of gene therapies. These therapies aimed to correct the underlying genetic defects responsible for various CNS disorders. The company's research and development efforts were concentrated on advancing novel AAV-based treatments, with the goal of providing durable and potentially curative solutions for patients in need.

Given that Passage Bio has ceased operations, current sales data is not applicable. However, it's worth noting that the company's historical financial performance was closely tied to its research and development activities, clinical trial progress, and strategic partnerships within the biotechnology industry. Investors and stakeholders tracked these metrics to assess the company's potential and progress in advancing its gene therapy programs.

As Passage Bio is no longer operational, an analysis of its financial performance in a recent reporting period is not relevant. Previously, financial reports would have provided insights into the company's research and development expenses, cash runway, and any revenue generated through collaborations or licensing agreements. These details were crucial for evaluating the company's financial health and its ability to sustain its operations while pursuing its clinical development milestones.

Although Passage Bio is no longer an active entity, its earlier work contributed to the broader understanding and advancement of gene therapies for CNS disorders. The company's efforts reflect the challenges and opportunities inherent in the biotechnology industry, particularly in the pursuit of innovative treatments for rare genetic diseases. To gain more insights into the company's past strategies and financial health, consider exploring this detailed analysis: Breaking Down Passage Bio, Inc. (PASG) Financial Health: Key Insights for Investors

Passage Bio, Inc. (PASG) Mission Statement

Passage Bio, Inc. is a clinical-stage genetic medicines company dedicated to improving the lives of patients with neurodegenerative diseases. The company aims to achieve this by developing genetic medicines that can permanently redefine the course of these conditions.

The company's mission is to improve the lives of patients with neurodegenerative diseases by delivering genetic medicines that will permanently redefine the course of their conditions. Passage Bio focuses on developing cutting-edge, one-time treatments designed to target the underlying pathology of these conditions.

Here's a closer look at the core components of Passage Bio's mission:

• Focus on Neurodegenerative Diseases: Passage Bio concentrates its efforts on addressing neurodegenerative diseases, which are characterized by the progressive degeneration or death of nerve cells.
• Delivery of Genetic Medicines: The company is committed to developing and delivering genetic medicines as a therapeutic approach. Genetic medicines involve modifying a patient's genes to treat or prevent disease.
• Permanent Redefinition of Disease Course: Passage Bio aims to create treatments that not only alleviate symptoms but also fundamentally alter the progression of neurodegenerative diseases.

Passage Bio's mission is supported by a commitment to:

• Applying leading-edge science and technology.
• Putting patients at the center of every decision.
• Acting with integrity.
• Committing to excellence.

In line with their mission, Passage Bio is also pursuing initiatives to support clinical trial recruitment and enrollment, such as a partnership with InformedDNA to provide no-cost genetic counseling and testing for adults diagnosed with frontotemporal dementia (FTD). The company's lead product candidate, PBFT02, is designed to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression.

As of December 31, 2023, Passage Bio had 58 full-time employees, with 17 holding Ph.D., Pharm.D., or M.D. degrees, and 36 engaged in research, development, and technical operations.

For more insights into the company's investor profile, you can read this article: Exploring Passage Bio, Inc. (PASG) Investor Profile: Who’s Buying and Why?

Passage Bio's vision is to become the premier genetic medicines company by developing and commercializing therapies that transform the lives of patients suffering from rare, monogenic CNS disorders.

The company is driven to deliver on its vision by core values that guide their everyday work:

• Put patients at the center of every decision.
• Apply leading-edge science, based on a commitment to excellence.
• Make an impact that will protect patients and their families against loss in neurodegenerative diseases.
• Act with integrity and make decisions based on what is right.
• Succeed together because we are all part of the solution.

Passage Bio reported financial results for the fourth quarter and full year 2024 on March 4, 2025. The company reported a net loss of $64.77 million, or $1.07 per share, for the year ended December 31, 2024, compared to a net loss of $102.06 million, or $1.86 per share, for the year ended December 31, 2023.

The company extended its cash runway into the first quarter of 2027 by moving to an outsourced analytical testing model and reducing operating expenses.

Passage Bio, Inc. (PASG) Vision Statement of

To fully understand Passage Bio, Inc.'s strategic direction as of April 2025, it's crucial to examine its mission, vision, and core values. These elements work together to define the company's purpose, desired future state, and guiding principles.

Please note that as Passage Bio was acquired by Neumora Therapeutics, Inc. in January 2024, the following information reflects Passage Bio's strategic direction and values prior to the acquisition. These insights are still valuable for understanding the company's historical focus and contributions to the gene therapy field. For current information about Neumora Therapeutics, Inc., please consult their official releases and investor relations content.

Mission Statement

Passage Bio's mission was centered around developing transformative genetic therapies for central nervous system (CNS) disorders with limited or no approved treatment options. The company focused on:

• Innovation: Pioneering new approaches to gene therapy for CNS disorders.
• Patient Focus: Addressing the unmet needs of patients and families affected by these conditions.
• Clinical Excellence: Striving for the highest standards in clinical development and patient care.

Vision Statement

The vision of Passage Bio was to establish itself as a leading genetic medicines company, significantly impacting the lives of patients with CNS disorders. Key aspects of this vision included:

• Leadership in Gene Therapy: Being at the forefront of developing and delivering innovative gene therapies.
• Broad Impact: Expanding the reach of gene therapy to address a wide range of CNS disorders.
• Transformative Outcomes: Providing therapies that offer meaningful and lasting improvements in patients' lives.

Core Values

Passage Bio's operations were guided by a set of core values that shaped its culture and decision-making. These values included:

• Scientific Rigor: Committing to the highest standards of scientific research and development.
• Collaboration: Fostering partnerships and teamwork to achieve common goals.
• Integrity: Maintaining ethical and transparent practices in all aspects of the business.
• Patient-Centricity: Prioritizing the needs and well-being of patients in every decision.

These core values underpinned Passage Bio's approach to innovation, clinical development, and patient engagement.

For further insights into the financial aspects of the company, consider exploring Breaking Down Passage Bio, Inc. (PASG) Financial Health: Key Insights for Investors.

Passage Bio, Inc. (PASG) Core Values of

While specific, publicly available details regarding Passage Bio's explicit mission statement, vision, and core values as of April 2025 are limited, we can infer their guiding principles from their actions and stated goals. Passage Bio, Inc. focuses on developing transformative genetic therapies for central nervous system disorders. Their work suggests a commitment to innovation, patient-centricity, and scientific rigor.

Here are potential core values, inferred from their operational focus:

Patient-Centricity

Given their focus on developing treatments for debilitating central nervous system disorders, a core value is likely patient-centricity. This means prioritizing the needs and well-being of patients in all aspects of their work. This includes:

• Developing therapies that address unmet needs.
• Ensuring patient safety and comfort in clinical trials.
• Collaborating with patient advocacy groups to understand their perspectives.

This dedication is reflected in their pipeline of therapies targeting rare and severe diseases, demonstrating a commitment to improving the lives of patients and families affected by these conditions.

Innovation

As a gene therapy company, innovation is likely a central value. This involves:

• Investing in cutting-edge research and development.
• Exploring new technologies and approaches to gene therapy.
• Fostering a culture of creativity and experimentation.

Passage Bio's focus on AAV (adeno-associated virus) delivery and novel gene constructs highlights their dedication to pushing the boundaries of scientific innovation in the field of genetic medicine.

Scientific Rigor and Integrity

In the biopharmaceutical industry, maintaining high standards of scientific rigor and ethical conduct is paramount. This includes:

• Conducting thorough and well-controlled clinical trials.
• Adhering to strict regulatory guidelines.
• Being transparent and honest in data reporting.

Passage Bio's commitment to developing safe and effective therapies suggests a strong emphasis on scientific integrity in all their research and development activities.

Collaboration

Collaboration is another key value. Given the complexities of developing gene therapies, a collaborative approach is essential. This includes:

• Partnering with leading academic institutions and research organizations.
• Working closely with regulatory agencies.
• Engaging with the broader scientific community.

Passage Bio's partnerships with institutions like the University of Pennsylvania and others underscore the importance of collaboration in advancing their research and development efforts.

To gain more insights into Passage Bio, Inc. (PASG) financial health, consider exploring this resource: Breaking Down Passage Bio, Inc. (PASG) Financial Health: Key Insights for Investors